378 related articles for article (PubMed ID: 30954969)
1. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
[TBL] [Abstract][Full Text] [Related]
2. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP
Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645
[TBL] [Abstract][Full Text] [Related]
3. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
van Mulligen E; Weel AE; Kuijper TM; Denissen NHAM; Gerards AH; de Jager MH; Lam-Tse WK; Hazes JM; van der Helm-van Mil A; de Jong PHP; Luime JJ
Ann Rheum Dis; 2020 Dec; 79(12):1550-1556. PubMed ID: 32907801
[TBL] [Abstract][Full Text] [Related]
4. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
5. The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients.
van Mulligen E; Weel AEAM; Kuijper TM; Hazes JMW; van der Helm-van Mil AHM; de Jong PHP
Semin Arthritis Rheum; 2020 Jun; 50(3):423-431. PubMed ID: 32224045
[TBL] [Abstract][Full Text] [Related]
6. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
7. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
8. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M
RMD Open; 2024 May; 10(2):. PubMed ID: 38816210
[TBL] [Abstract][Full Text] [Related]
9. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
11. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
[TBL] [Abstract][Full Text] [Related]
15. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
[TBL] [Abstract][Full Text] [Related]
17. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
19. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis.
Simpson E; Hock E; Stevenson M; Wong R; Dracup N; Wailoo A; Conaghan P; Estrach C; Edwards C; Wakefield R
Health Technol Assess; 2018 Apr; 22(20):1-258. PubMed ID: 29712616
[TBL] [Abstract][Full Text] [Related]
20. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]